Furthermore, sotagliflozin, a non-selective SGLT inhibitor acting on both SGLT1 and 2 [16], with strong affinity for SGLT2 and mild selectivity for SGLT1, has been developed and, recently, the results of two randomized controlled trials focusing on heart failure and renal outcomes of sotaglifozin-treatment were published [17,18]. This evidence concerns the gene SLC5A2 and heart failure.